Research News
View articles by month and year
-
Tykerb May Treat Herceptin-Resistant HER2-Positive Breast Cancer
Research on cells suggests that HER2-positive breast cancers resistant to Herceptin may respond to Tykerb.
-
Herceptin May Destroy Cancer Stem Cells
Preliminary research using math formulas suggests that HER2-negative breast cancers may benefit from Herceptin.
-
HER2 Levels Drop If HER2-Positive Cancers Respond to Chemo Plus Herceptin Before Surgery
New research suggests that measuring the drop in blood HER2 protein levels before and after chemotherapy and Herceptin given before surgery may help predict which women are most likely to benefit from Herceptin treatment before surgery.
-
Herceptin Plus Chemo Before Surgery Better Than Chemo Alone for HER2-Positive Locally-Advanced Disease
Research suggests that giving Herceptin at the same time as chemotherapy BEFORE surgery for HER2-positive locally advanced or inflammatory breast cancer can lengthen the time before the cancer comes back or grows compared to chemotherapy alone.
-
Herceptin Plus Tykerb Improves Survival for Women with Metastatic HER2-Positive Breast Cancer
HER2-positive, metastatic breast cancer that grows while being treated with Herceptin seems to benefit from adding Tykerb to the Herceptin rather than switching from Herceptin to Tykerb.
-
Timing of Herceptin Influences Risk of Recurrence
Research suggests that giving Herceptin at the same time as chemotherapy, rather than after chemotherapy is done, can reduce the risk of recurrence of HER2-positive, early-stage breast cancer.
-
Even Small HER2-Positive Cancers Have Higher Recurrence Risk
Small (1 cm or smaller), early-stage, HER2-positive breast cancers are more likely to come back (recur) and spread to parts of the body away from the breast (metastasize) than small, early-stage HER2-negative breast cancers, which suggests that treating these cancers with Herceptin (chemical name: trastuzumab) may make sense.
-
Even Small HER2-Positive Cancers Have Higher Recurrence Risk
Small (1 cm or smaller), early-stage, HER2-positive breast cancers are more likely to come back (recur) and spread to parts of the body away from the breast (metastasize) than small, early-stage HER2-negative breast cancers, which suggests that treating these cancers with Herceptin (chemical name: trastuzumab) may make sense.
-
Herceptin Helps Treat Early-Stage, HER2-Positive Cancers
New research shows that Herceptin (chemical name: trastuzumab) offers benefits to women diagnosed with HER2-positive, early-stage breast cancer with a low risk of recurrence.
-
Some Estrogen-Receptor-Negative Breast Cancers Become Estrogen-Receptor-Positive After Herceptin Treatment
A new study found that some HER2-positive, estrogen-receptor-negative breast cancer cells became estrogen-receptor-positive after being exposed to Herceptin (chemical name: trastuzumab). The study was done on groups of cells in a lab, not in people.
